Skip to content
DataLookout
Menu

GROUPNCT06297252

Prevalence of Psychiatric Disorders During Pregnancy at 2nd Trimester Ultrasound: a Feasibility Study in the General Population

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 2
    • Primary completion date: Mar 2026 to Apr 24, 2026
    • Study completion date: Sep 2026 to Oct 24, 2026
    • Start date changed from estimate of Mar 2024 to Apr 25, 2024
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To determine the prevalence of the presence of at least one characterized psychiatric disorder, in remission or not, during pregnancy, at the time of the second-trimester ultrasound (T2 ultrasound) based on a standardized clinical assessment.
Timeframe: Baseline (T2 ultrasound)

Secondary (28)

To determine the prevalence of each psychiatric disorder characterized during pregnancy at the time of the second-trimester ultrasound, based on a standardized clinical assessment.
Determine comorbidity profiles across all pathologies, describing whether there are patient groups based on these profiles.
Compare the prevalence of psychiatric disorders unknown to the obstetrics team with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound.
Compare the prevalence of psychiatric disorders unknown to the patient with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound.
Compare the prevalence of psychiatric disorders unknown to the general practitioner with the prevalence of known psychiatric disorders in pregnant patients at the time of T2 ultrasound.
Show 23 moreShow less
Assess patients' medication compliance using self-administered questionnaires (MARS).
Assess patients' treatment beliefs using self-administered questionnaires (BMQ).
Determine the sociodemographic, psychological, psychiatric, medical and obstetric factors, as well as those associated with access to care and the care pathway associated with known or unknown diagnoses during pregnancy.
Determine the properties (sensitivity) of screening questionnaires (EPDS) for psychiatric disorders in this population.
Determine the properties (specificity) of screening questionnaires (EPDS) for psychiatric disorders in this population.
Determine the properties (positive predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population.
Determine the properties (negative predictive value) of screening questionnaires (EPDS) for psychiatric disorders in this population.
Determine the properties (sensitivity) of screening questionnaires ( MDQ) for psychiatric disorders in this population.
Determine the properties (specificity) of screening questionnaires ( MDQ) for psychiatric disorders in this population.
Determine the properties (positive predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population.
Determine the properties (negative predictive value) of screening questionnaires ( MDQ) for psychiatric disorders in this population.
Determine the properties (sensitivity) of screening questionnaires (PCL-5) for psychiatric disorders in this population.
Determine the properties (specificity) of screening questionnaires (PCL-5) for psychiatric disorders in this population.
Determine the properties (positive predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population.
Determine the properties (negative predictive value) of screening questionnaires (PCL-5) for psychiatric disorders in this population.
Determine the properties (sensitivity) of screening questionnaires (EDEQ) for psychiatric disorders in this population.
Determine the properties (specificity) of screening questionnaires (EDEQ) for psychiatric disorders in this population.
Determine the properties (positive predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population.
Determine the properties (negative predictive value) of screening questionnaires (EDEQ) for psychiatric disorders in this population.
Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (PAI).
Compare mother-child bonding difficulties between patients with and without a psychiatric diagnosis at the time of the study, using scales (MIBS).
Describe how the study will be carried out, either in person or by teleconsultation, and the reasons for this choice.
Determine the prevalence of each psychiatric disorder at two months post-inclusion based on a standardized clinical assessment.

Arms and interventions

Pregnant adultsExperimental

Adults women with an ongoing pregnancy who are scheduled for a T2 ultrasound, regardless of known history or pregnancy context (normal or pathological).

Diagnostic tests: standardized clinical psychiatric evaluations, self-administered psychiatric questionnaire assessments

Other: blood sampling

Sites

2 sites in 1 country